Zacks Small Cap Research on MSN3d
GRCE: Initiating Coverage – From Confusion to Infusion(NASDAQ:GRCE) with a valuation of $12.50 per share. This value is based on our estimates for the successful development and commercialization of GTX-104 in patients being treated for aneurysmal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback